EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION
Aim. To study the efficacy of rosuvastatin in dyslipidemia correction in patients after Q-wave myocardial infarction (Q-MI).Material and methods. 40 patients (aged 52.7±9.4 years old) were included into the study after 10-14 days of the acute Q-MI onset. Determination of blood lipids profile, alanin...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227978337157120 |
|---|---|
| author | R. D. Kurbanov N. U. Zakirov Y. G. Kevorkova N. B. Sayfiddinova |
| author_facet | R. D. Kurbanov N. U. Zakirov Y. G. Kevorkova N. B. Sayfiddinova |
| author_sort | R. D. Kurbanov |
| collection | DOAJ |
| description | Aim. To study the efficacy of rosuvastatin in dyslipidemia correction in patients after Q-wave myocardial infarction (Q-MI).Material and methods. 40 patients (aged 52.7±9.4 years old) were included into the study after 10-14 days of the acute Q-MI onset. Determination of blood lipids profile, alanine and asparagine transaminase levels was included into the initial examination. Rosuvastatin in a fixed dose of 20 mg/day was prescribed to the patients as a part of the standard therapy. Depending on the dynamics of the investigated parameters the individual doses of rosuvastatin were adjusted from 10 to 40 mg/day after 1 month of therapy. Final evaluation of blood lipids profile and transaminase levels was performed in the next 2 months of therapy.Results. Rosuvastatin 20 mg/day for 1 month in patients with an acute Q-MI provides a significant decrease in low-density lipoprotein (LDL) cholesterol level by 21.4%, and achievement of target levels of this parameter in 59.5% of patients. Rosuvastatin dose adjustment was required in 48.6% of patients after 1 month of therapy. Individually adjusted rosuvastatin doses provided the achievement of LDL cholesterol target levels by the end of the third month of treatment in 91% of patients. Elevated liver transaminase levels were observed in 7.5% of patients after 1 month of treatment. There were no new cases of adverse events after 3 months of therapy.Conclusion. Rosuvastatin 10-40 mg/day is effective and safe medicine for the treatment of dyslipidemia in patients after acute Q-MI. |
| format | Article |
| id | doaj-art-ec0085e3dd0647709d3560237a3dfa3a |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-ec0085e3dd0647709d3560237a3dfa3a2025-08-23T10:00:17ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-0110552552910.20996/1819-6446-2014-10-5-525-529212EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTIONR. D. Kurbanov0N. U. Zakirov1Y. G. Kevorkova2N. B. Sayfiddinova3Republican Specialized Center for CardiologyRepublican Specialized Center for CardiologyRepublican Specialized Center for CardiologyRepublican Specialized Center for CardiologyAim. To study the efficacy of rosuvastatin in dyslipidemia correction in patients after Q-wave myocardial infarction (Q-MI).Material and methods. 40 patients (aged 52.7±9.4 years old) were included into the study after 10-14 days of the acute Q-MI onset. Determination of blood lipids profile, alanine and asparagine transaminase levels was included into the initial examination. Rosuvastatin in a fixed dose of 20 mg/day was prescribed to the patients as a part of the standard therapy. Depending on the dynamics of the investigated parameters the individual doses of rosuvastatin were adjusted from 10 to 40 mg/day after 1 month of therapy. Final evaluation of blood lipids profile and transaminase levels was performed in the next 2 months of therapy.Results. Rosuvastatin 20 mg/day for 1 month in patients with an acute Q-MI provides a significant decrease in low-density lipoprotein (LDL) cholesterol level by 21.4%, and achievement of target levels of this parameter in 59.5% of patients. Rosuvastatin dose adjustment was required in 48.6% of patients after 1 month of therapy. Individually adjusted rosuvastatin doses provided the achievement of LDL cholesterol target levels by the end of the third month of treatment in 91% of patients. Elevated liver transaminase levels were observed in 7.5% of patients after 1 month of treatment. There were no new cases of adverse events after 3 months of therapy.Conclusion. Rosuvastatin 10-40 mg/day is effective and safe medicine for the treatment of dyslipidemia in patients after acute Q-MI.https://www.rpcardio.online/jour/article/view/212myocardial infarctionlipidslow-density lipoprotein cholesterolliver transaminase |
| spellingShingle | R. D. Kurbanov N. U. Zakirov Y. G. Kevorkova N. B. Sayfiddinova EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION Рациональная фармакотерапия в кардиологии myocardial infarction lipids low-density lipoprotein cholesterol liver transaminase |
| title | EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION |
| title_full | EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION |
| title_fullStr | EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION |
| title_full_unstemmed | EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION |
| title_short | EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION |
| title_sort | efficacy of rosuvastatin in dyslipidemia correction in patients after q wave myocardial infarction |
| topic | myocardial infarction lipids low-density lipoprotein cholesterol liver transaminase |
| url | https://www.rpcardio.online/jour/article/view/212 |
| work_keys_str_mv | AT rdkurbanov efficacyofrosuvastatinindyslipidemiacorrectioninpatientsafterqwavemyocardialinfarction AT nuzakirov efficacyofrosuvastatinindyslipidemiacorrectioninpatientsafterqwavemyocardialinfarction AT ygkevorkova efficacyofrosuvastatinindyslipidemiacorrectioninpatientsafterqwavemyocardialinfarction AT nbsayfiddinova efficacyofrosuvastatinindyslipidemiacorrectioninpatientsafterqwavemyocardialinfarction |